Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10:32aLowe Brockenbrough & Co. Inc. Cuts Stake in AbbVie Inc. $ABBV  
10:11aAbbVie Inc. $ABBV Stake Increased by Telemus Capital LLC  
10/20AbbVie downgraded by Zacks Investment Research to hold.  
10/20AbbVie Inc. $ABBV Lifted to “Buy” at Zacks Investment Research  
10/20AbbVie Inc. $ABBV Sets New 12-Month High at $94.41  
10/20AbbVie Inc. $ABBV Scheduled to Post Quarterly Earnings on Friday  
10/20Get the latest news and updates for $JPM $APPS $ABBV $HTA $WHF automatically .. 
10/19$ABBV $150 Billion out of control 
10/19SWING TRADE ALERT: $ABBV technical alerts: MACD Bullish Signal Line Cross, Ex.. 
10/19AbbVie Inc. $ABBV Shares Bought by Enterprise Financial Services Corp  
10/19AbbVie Inc. $ABBV Shares Bought by Enterprise Financial Services Corp  
10/19AbbVie Inc. $ABBV Price Target Raised to $115.00  
10/18? TODAY'S ACTIVE FLOW: $BAC $AAPL $IBM $NFLX $FB $MU $TSLA $BABA $NVDA $JD $C..
1
10/18Najarian Brothers See Unusual Option Activity in $IBM, $XLF, $PG & $ABBV ..
2
10/18Najarian Brothers See Unusual Option Activity in $IBM, $XLF, $PG & $ABBV ..
3
10/18Where can you find value in healthcare stocks? $ABBV $GILD $BIIB $TEVA $AET  
10/18Goldman Sachs says to swap Celgene for AbbVie:
1
10/18SWING TRADE ALERT: Recent $ABBV technical alerts: New 52 Week Closing High pl.. 
10/18$ABBV REPEAT BULL SWEEPERS DETECTED, AGAIN!
2
10/18$ABBV: AbbVie and Harpoon Therapeutics have entered an immuno-oncology resear..
2
10/18AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaborati.. 
10/18AbbVie to Present at the 2017 Credit Suisse Health Care Conference  
10/18AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% pr..
1
10/18BRIEF-Abbvie and harpoon therapeutics announce immuno-oncology research colla.. 
10/18Arix Bioscience : notes Harpoon AbbVie IO collaboration  
10/18Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration wit.. 
10/18AbbVie : and Harpoon Therapeutics Announce Immuno-Oncology Research Collabora.. 
10/18AbbVie : to Present at the 2017 Credit Suisse Health Care Conference  
10/18AbbVie Inc. $ABBV Stake Raised by Whitnell & Co.  
10/17As is $145 B for $ABBV and $119 B for $NVDA .... things getting whacky $QQQ
1
10/17Ingalls & Snyder LLC Grows Position in AbbVie Inc. $ABBV  
10/17AbbVie Inc. $ABBV Position Held by River Wealth Advisors LLC  
10/17First Western Capital Management Co Has $823,000 Stake in AbbVie Inc. $ABBV  
10/16Just noticed $ABBV market cap at $145 Billion. Insane !
1
10/16Abbvie $ABBV PT Raised to $115 at Jefferies  
10/16TG Therapeutics down 20% premarket on potential extended timeline for U.S. ma.. 
10/16AbbVie's PT raised by Jefferies Group LLC to $115.00. buy rating.  
10/16Bristol-Myers downgraded to Hold from Buy at Jefferies $BMY $ABBV
3
10/16$ABBV - AbbVie Inc. #ABBV Position Held by NJ State Employees Deferred Compen.. 
10/16AbbVie Inc. $ABBV Position Held by NJ State Employees Deferred Compensation P.. 
10/15AbbVie Inc. $ABBV Stake Lifted by Accuvest Global Advisors  
10/15Stewart & Patten Co. LLC Has $1,128,000 Position in AbbVie Inc. $ABBV  
10/15$ABBV - AbbVie Inc #ABBV Price Target Raised to $90.00  
10/15$ABBV - AbbVie Inc #ABBV PT Raised to $90.00  
10/14AbbVie Inc $ABBV Given New $90.00 Price Target at Barclays PLC  
10/14AbbVie Inc. $ABBV Upgraded at Cowen and Company  
10/14Fundamental Equity Analysis – Consolidated Research on Johnson & Johnson,.. 
10/13Barclays Keeps a Hold Rating on AbbVie $ABBV  
10/13AbbVie stock price target raised to $95 from $92 from UBS #news 
10/13AbbVie’s $ABBV Neutral Rating Reiterated at UBS AG  
More tweets
Qtime:182
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 938 M
Net income 2017 7 351 M
Debt 2017 25 677 M
Yield 2017 2,70%
P/E ratio 2017 20,17
P/E ratio 2018 16,40
EV / Sales 2017 6,40x
EV / Sales 2018 5,66x
Capitalization 153 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.37%153 193
MERCK KGAA-4.68%14 304
KYOWA HAKKO KIRIN CO LTD24.97%10 266
JAZZ PHARMACEUTICALS PLC28.83%8 652
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 811
CONVATEC GROUP-9.02%5 505